Statera Biopharma, Inc.: 10-Q filed 2020-05-15
What Statera Biopharma, Inc. reported in its quarterly report filed 2020-05-15 (fiscal Q1 2020): 29 published measures, 61 facts as tagged in accession 0001437749-20-010885.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2020-05-15
- Fiscal period
- fiscal Q1 2020
- Accession
- 0001437749-20-010885 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Statera Biopharma, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 1,864,586 | USD | |
| At 2019-12-31 | 2,036,852 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 1,085,222 | USD | |
| At 2019-12-31 | 1,052,566 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | -4,213,695 | USD | |
| At 2019-12-31 | -4,055,592 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 1,058,811 | USD | |
| At 2019-12-31 | 1,126,124 | USD | |
| At 2019-03-31 | 2,798,817 | USD | |
| At 2018-12-31 | 3,617,234 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -588,532 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -872,943 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -425,593 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -827,855 | USD | 90 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 156,042 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 197,919 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 382,215 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | -167,294,104 | USD | |
| At 2019-12-31 | -166,705,572 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 0 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 0 | USD | 90 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 12,434 | USD | |
| At 2019-12-31 | 15,514 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -444,332 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -790,172 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 1,833,485 | USD | |
| At 2019-12-31 | 2,002,671 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 1,085,222 | USD | |
| At 2019-12-31 | 1,052,566 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 266,058 | USD | |
| At 2019-12-31 | 263,573 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 334,436 | USD | |
| At 2019-12-31 | 378,865 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 600,374 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 988,091 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 218,208 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 513,421 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 11,403,239 | shares | |
| At 2019-12-31 | 11,298,239 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | -642,507 | USD | |
| At 2019-12-31 | -568,030 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 779,364 | USD | |
| At 2019-12-31 | 984,286 | USD | |
| At 2019-03-31 | 2,761,465 | USD | |
| At 2018-12-31 | 3,614,027 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 18,667 | USD | |
| At 2019-12-31 | 18,667 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 774,752 | USD | |
| At 2019-12-31 | 782,579 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -601,728 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -893,312 | USD | 90 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -663,009 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -846,184 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 382,166 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 474,670 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 3,080 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 3,915 | USD | 90 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 2,900 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -7,648 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -157,396 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -103,140 | USD | 90 |
Inspect the source
- Entity
- Statera Biopharma, Inc. / CIK 0001318641
- Captured
- SEC response SHA-256
9e499247f86d1cf9ca87ba87bfcdf37d42baa7907f4baa6e983f1992a49045f7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001318641.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))